^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BVAC-C

    i
    Associations
    News

    Trials

    Company:
    Cellid
    Drug class:
    Immunostimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    Safety and Tolerability Evaluation Study of BVAC-C in Patients With HPV Type 16 or 18 Positive Cervical Cancer (BVAC-C-P1) (NCT02866006)
    Phase 1/2
    Cellid Co., Ltd.
    Completed
    Last update posted :
    10/12/2022
    Initiation :
    10/01/2016
    Primary completion :
    12/01/2021
    Completion :
    06/01/2022
    CD4
    |
    topotecan • BVAC-C